Publications by authors named "ALESSANDRINI H"
Background: Transcatheter tricuspid valve intervention (TTVI) has been increasingly adopted in recent years for the treatment of patients with tricuspid regurgitation (TR). However, no dedicated risk stratification has been established for patients undergoing TTVI.
Objectives: The aim of the present study was to propose a dedicated risk score for patients affected by severe TR undergoing TTVI.
Article Synopsis
- Doctors are studying how a procedure called transcatheter tricuspid valve interventions (TTVI) affects patients with heart issues, specifically focusing on something called mitral regurgitation (MR) after the procedure.
- They looked at data from a big group of patients and found that many showed improvement in MR after the procedure, but some got worse.
- They discovered that certain factors, like successful procedures and specific treatments, could help predict whether a patient’s MR would improve or get worse after TTVI.
Article Synopsis
- * It found that patients with mild residual TR had an 85% survival rate, while those with moderate and severe TR had significantly lower rates of 70% and 44%, respectively.
- * The research emphasizes the need for a more detailed classification of TR severity to better predict patient outcomes and highlights the goal of achieving at least mild to moderate residual TR for successful interventions.
Article Synopsis
- The study examines the effectiveness of the TRI-SCORE in predicting outcomes for patients undergoing transcatheter tricuspid valve intervention (TTVI), using data from a large, international registry called TriValve.
- Among the 634 patients analyzed, those with a TRI-SCORE of 8 or higher were found to have a significantly increased risk of all-cause mortality and complications within 30 days of the procedure, compared to those with lower TRI-SCOREs.
- Despite indicating a higher risk for severe outcomes, the TRI-SCORE overall showed limited effectiveness in predicting clinical results following TTVI, as improvements in patient functional class were observed across all TRI-SCORE levels.
Aims: T-TEER is an effective therapy for the treatment of tricuspid regurgitation (TR). However, the effects of leaflets clipping on tricuspid valve annulus (TA) have not been investigated in detail. The aim of this study is to investigate the effects of tricuspid transcatheter edge-to-edge repair (T-TEER) on TA diameter.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how pulmonary hypertension (PH) affects survival rates after a specific heart procedure called mitral transcatheter edge-to-edge repair (M-TEER), using updated definitions from recent guidelines.
- It analyzes data from 449 patients, classifying them into different types of PH and comparing their outcomes based on invasive measurements of heart pressures.
- Results indicate that patients with any form of PH have a significantly higher risk of death post-M-TEER compared to those without PH, reinforcing the importance of accurately diagnosing and categorizing PH to improve patient management.
Article Synopsis
- The study aimed to compare the characteristics and outcomes of patients with atrial STR (ASTR) and ventricular STR (VSTR) who underwent transcatheter edge-to-edge repair (T-TEER) for tricuspid regurgitation (TR).
- Patients were categorized into ASTR or VSTR based on specific cardiac criteria, and a total of 298 were included in the analysis, with similar procedural success rates for both groups.
- Results showed that while T-TEER effectively reduced TR in both ASTR and VSTR patients, survival rates at 12 months were significantly higher for ASTR (91%) compared to VSTR (72%).
Article Synopsis
- This study examines the relationship between tricuspid valve gradient (TVG) and clinical outcomes in patients who underwent tricuspid transcatheter edge-to-edge repair (TEER) for significant tricuspid regurgitation.
- Researchers analyzed data from 308 patients and categorized them into quartiles based on their mean TVG at discharge.
- The results showed no significant differences in mortality or heart failure hospitalizations across the TVG quartiles one year post-procedure, indicating that higher discharge TVG was not linked to worse outcomes.
Aims: The impact of sexuality in patients with significant tricuspid regurgitation (TR) undergoing transcatheter tricuspid valve intervention (TTVI) is unknown. The aim of this study was to investigate sex-specific outcomes in patients with significant TR treated with TTVI vs. medical therapy alone.
View Article and Find Full Text PDFArticle Synopsis
- The study examined the relationship between right ventricular (RV) and pulmonary arterial (PA) function, focusing on how effectively the RV works against the pressure in the PA in patients with tricuspid regurgitation (TR) undergoing valve repair or replacement.
- Researchers measured the RV-PA coupling ratio by using echocardiograms before and after the procedure, with a key focus on the impact of this ratio on 1-year mortality.
- Findings showed that a higher RV-PA coupling ratio was linked to lower mortality rates, indicating that improved RV function is crucial for better outcomes post-surgery in patients with TR.
Iatrogenic mitral stenosis following transcatheter mitral valve repair (TMVR) for relevant mitral regurgitation (MR) is a potential adverse side-effect, known to affect long-term outcome. However, only few determinants of an elevated mean transmitral pressure gradient (TMPG) have been described thus far. We sought to develop an integrative model for the prediction of TMPG following MitraClip (MC) therapy.
View Article and Find Full Text PDFBackground: Severe tricuspid regurgitation (TR) has limited treatment options and is associated with high morbidity and mortality.
Aims: We evaluated the safety and effectiveness of the Cardioband tricuspid valve reconstruction system from the ongoing European single-arm, multicentre, prospective TriBAND post-market clinical follow-up study.
Methods: Eligible patients had chronic symptomatic functional TR despite diuretic therapy and were deemed candidates for transcatheter tricuspid repair by the local Heart Team.
Background: Tricuspid regurgitation (TR) has a poor prognosis and limited treatment options and is frequently accompanied by right ventricular (RV) dysfunction. Transcatheter tricuspid valve interventions (TTVI) to reduce TR have been shown to be safe and feasible with encouraging early results. Patient selection for TTVI remains challenging, with the role of right ventricular (RV) function being unknown.
View Article and Find Full Text PDFBackground: Scarce data exist on patients with previous left valve surgery (PLVS) undergoing transcatheter tricuspid valve intervention (TTVI). This study sought to investigate the procedural and early outcomes in patients with PLVS undergoing TTVI.
Methods: This was a subanalysis of the multicenter TriValve registry including 462 patients, 82 (18%) with PLVS.
Background: Scarce data exist on patients with right ventricular dysfunction (RVD) or pulmonary hypertension (PH) undergoing transcatheter tricuspid valve intervention. This study aimed to determine the early and midterm outcomes and the factors associated with mortality in this group of patients.
Methods: This subanalysis of the multicenter TriValve (Transcatheter Tricuspid Valve Therapies) registry included 300 patients with severe tricuspid regurgitation with RVD (n=244), PH (n=127), or both (n=71) undergoing transcatheter tricuspid valve intervention.
Article Synopsis
- The study looked at patients who didn’t do well after a heart valve treatment called TMVR and checked their survival after trying other treatments.
- Out of 824 patients treated, 63 had problems, with some getting another MitraClip procedure and others having open-heart surgery.
- The results showed that surgery is better for certain patients, and those with heart issues like atrial fibrillation have a higher chance of not surviving after these second treatments.
Aims: Tricuspid regurgitation (TR) is associated with high morbidity and mortality rates with limited treatment options. We report one- and two-year outcomes of the Cardioband tricuspid valve reconstruction system in the treatment of ≥moderate functional TR in the TRI-REPAIR study.
Methods And Results: Thirty patients were enrolled in this single-arm, multicentre, prospective study.
Objectives: The aim of this study was to assess the clinical outcome of baseline massive or torrential tricuspid regurgitation (TR) after transcatheter tricuspid valve intervention (TTVI).
Background: The use of TTVI to treat symptomatic severe TR has been increasing rapidly, but little is known regarding the impact of massive or torrential TR beyond severe TR.
Methods: The study population comprised 333 patients with significant symptomatic TR from the TriValve Registry who underwent TTVI.
Objectives: The aim of this study was to assess the value of echocardiographic right ventricular (RV) and systolic pulmonary artery pressure (sPAP) assessment in predicting transcatheter tricuspid edge-to-edge valve repair (TTVR) outcome.
Background: RV dysfunction and pulmonary hypertension are associated with poor prognosis and are systematically sought during tricuspid regurgitation evaluation. The value of echocardiographic assessment in predicting TTVR outcome is unknown.
Objectives: The interference of a transtricuspid cardiac implantable electronic device (CIED) lead with tricuspid valve function may contribute to the mechanism of tricuspid regurgitation (TR) and poses specific therapeutic challenges during transcatheter tricuspid valve intervention (TTVI). Feasibility and efficacy of TTVI in presence of a CIED is unclear.
Background: Feasibility of TTVI in presence of a CIED lead has never been proven on a large basis.
Background: Tricuspid regurgitation is associated with increased rates of heart failure (HF) and mortality. Transcatheter tricuspid valve interventions (TTVI) are promising, but the clinical benefit is unknown.
Objectives: The purpose of this study was to investigate the potential benefit of TTVI over medical therapy in a propensity score matched population.
Objectives: The purpose of this study was to evaluate procedural and 1-year clinical and echocardiographic outcomes of patients treated with tricuspid edge-to-edge repair.
Background: Transcatheter edge-to-edge repair has been successfully performed in selected patients with symptomatic tricuspid regurgitation (TR) and high risk for surgery, but outcome data are sparse.
Methods: This analysis of the multicenter international TriValve (Transcatheter Tricuspid Valve Therapies) registry included 249 patients with severe TR treated with edge-to-edge repair in compassionate and/or off-label use.